Return to Today's science sparks archives

2014-07-01

Fig 2. Nucleosomal demethylation by LSD1 and Rcor proteins.

Fig 2. Nucleosomal demethylation by LSD1 and Rcor proteins.
  • Upadhyay G, Chowdhury AH, Vaidyanathan B, Kim D, Saleque S

  • Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):8071-6.

2014-07-02

Fig 1a. The cMethDNA assay. A, reference DNA (50 copies of each gene-specific standard; STD) was spiked into 300 μL serum and total DNA was purified.

Fig 1a. The cMethDNA assay. A, reference DNA (50 copies of each gene-specific standard; STD) was spiked into 300 μL serum and total DNA was purified.
  • Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S

  • Cancer Res. 2014 Apr 15;74(8):2160-70.

2014-07-03

Fig 3. Genome-wide Conservation Analyses of the Human and Mouse Prostate Cancer Interactomes. (A) ARACNe subnetworks from the human and mouse prostate cancer interactomes highlighting selected conserved transcriptional regulators. The scaled size of the transcriptional regulator nodes (colored circles) indicates the degree of conservation while the relative distance between them approximates the strength of their association.

Fig 3. Genome-wide Conservation Analyses of the Human and Mouse Prostate Cancer Interactomes. (A) ARACNe subnetworks from the human and mouse prostate cancer interactomes highlighting selected conserved transcriptional regulators. The scaled size of the transcriptional regulator nodes (colored circles) indicates the degree of conservation while the relative distance between them approximates the strength of their association.
  • Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, Eastham JA, Gopalan A, Pienta KJ, Shen MM, Califano A, Abate-Shen C

  • Cancer Cell. 2014 May 12;25(5):638-51

2014-07-07

Type 2 parastomal hernia demonstrating progressive fat herniation during 30 months of followup.

Type 2 parastomal hernia demonstrating progressive fat herniation during 30 months of followup.
  • Donahue TF, Bochner BH, Sfakianos JP, Kent M, Bernstein M, Hilton WM, Cha EK, Yee AM, Dalbagni G, Vargas HA

  • J Urol. 2013 Dec 30. pii: S0022-5347(13)06208-3.

2014-07-08

Fig 1. Patient allocation to treatment cohorts.

Fig 1. Patient allocation to treatment cohorts.
  • Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker A, Vitale L, Yellin M, Davis T, Keler T

  • Sci Transl Med. 2014 Apr 16;6(232):232ra51

2014-07-09

Graphical Abstract

Graphical Abstract
  • Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N

  • Cancer Cell. 2014 May 12;25(5):697-710.

2014-07-10

Fig 7. Proposed model for differentiation pathways and commitments of cDC, pDC, T cell, and thymic NK cell lineages.

Fig 7. Proposed model for differentiation pathways and commitments of cDC, pDC, T cell, and thymic NK cell lineages.
  • Kyoizumi S, Kubo Y, Kajimura J, Yoshida K, Hayashi T, Nakachi K, Young LF, Moore MA, van den Brink MR, Kusunoki Y

  • J Immunol. 2014 Jun 15;192(12):5749-60.

2014-07-11

Correlating maximum dose to brachial plexus (left or right) with primary gross tumor volume devised by tumor subsite (oropharynx, hypopharynx, and larynx compared with nasopharynx, oral cavity, and others).

Correlating maximum dose to brachial plexus (left or right) with primary gross tumor volume devised by tumor subsite (oropharynx, hypopharynx, and larynx compared with nasopharynx, oral cavity, and others).
  • Romesser PB, Qureshi MM, Kovalchuk N, Truong MT

  • Med Dosim. 2014 Summer;39(2):169-73.

2014-07-14

Fig 1. Agarose gel electrophoresis images and analysis of gel images and old (4–10 months) DNA:SWCNT samples, set one.

Fig 1. Agarose gel electrophoresis images and analysis of gel images and old (4–10 months) DNA:SWCNT samples, set one.
  • Williams RM, Nayeem S, Dolash BD, Sooter LJ

  • PLoS One. 2014 Apr 4;9(4):e94117.
Open Access button

2014-07-15

Fig 1. Generated cell lines were characterized.  (C) Immunofluorescence microscopy for RET (red), GFRα1 (green), and DAPI (blue) in generated MiaPaCa-2 and 3T3 cell lines.

Fig 1. Generated cell lines were characterized. (C) Immunofluorescence microscopy for RET (red), GFRα1 (green), and DAPI (blue) in generated MiaPaCa-2 and 3T3 cell lines.
  • He S, Chen CH, Chernichenko N, He S, Bakst RL, Barajas F, Deborde S, Allen PJ, Vakiani E, Yu Z, Wong RJ

  • Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2008-17

2014-07-16

Fig 4.  Up-regulation of FOXN1 in NT2/D1 cells promotes expression of epithelial marker genes. (B) Expression level of epithelial markers in FOXN1 up-regulated NT2/D1 cells by RT-PCR. **P<0.01; *P<0.05.

Fig 4.  Up-regulation of FOXN1 in NT2/D1 cells promotes expression of epithelial marker genes. (B) Expression level of epithelial markers in FOXN1 up-regulated NT2/D1 cells by RT-PCR. **P<0.01; *P<0.05.
  • Kushwaha R, Thodima V, Tomishima MJ, Bosl GJ, Chaganti RS

  • Stem Cells Dev. 2014 May 15;23(10):1149-56.

2014-07-17

Fig 1. Scatterplot demonstrating the correlation of radiation oncologist–delineated positron emission tomography (PET) and computed tomography (CT) gross tumor volumes (cm3) in log scale.

Fig 1. Scatterplot demonstrating the correlation of radiation oncologist–delineated positron emission tomography (PET) and computed tomography (CT) gross tumor volumes (cm3) in log scale.
  • Terezakis SA, Schöder H, Kowalski A, McCann P, Lim R, Turlakov A, Gonen M, Barker C, Goenka A, Lovie S, Yahalom J

  • Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):376-83.

2014-07-21

Fig 2. Overall survival by treatment group: erlotinib, whole brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS).

Fig 2. Overall survival by treatment group: erlotinib, whole brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS).
  • Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu HA, Chan TA, Zhang Z, Wu AJ

  • Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):322-9.

2014-07-22

Fig 6d. Fluorescent microscopic images of tumors from KitV558del/+ mice treated for 10 weeks, followed by a single injection of Hoechst dye and fluorescein-conjugated lectin.

Fig 6d. Fluorescent microscopic images of tumors from KitV558del/+ mice treated for 10 weeks, followed by a single injection of Hoechst dye and fluorescein-conjugated lectin.
  • Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, Crawley MH, Green BL, Popow R, Pillarsetty N, Veach DR, Ku AT, Rossi F, Besmer P, Antonescu CR, Zeng S, Dematteo RP

  • Clin Cancer Res. 2014 May 1;20(9):2350-62.

2014-07-23

Fig 1. Reduction of PI3K and mTORC1/mTORC2 pathway signaling by SAR245409 in serial hair and skin samples.

Fig 1. Reduction of PI3K and mTORC1/mTORC2 pathway signaling by SAR245409 in serial hair and skin samples.
  • Papadopoulos KP, Tabernero J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, Lorusso PM

  • Clin Cancer Res. 2014 May 1;20(9):2445-56.

2014-07-24

Fig 1. Schematics of the walk-through study using TRCN#40273. 
Hairpin cleavage variants identified for the entire length of the oligonucleotide with a step size of 1.

Fig 1. Schematics of the walk-through study using TRCN#40273. Hairpin cleavage variants identified for the entire length of the oligonucleotide with a step size of 1.
  • Bhinder B, Shum D, Li M, Ibáñez G, Vlassov AV, Magdaleno S, Djaballah H.

  • PLoS One. 2014 Jul 2;9(7):e100676
Open Access button

2014-07-25

Sustained Knockdown of CD95L Induces Cell Death.

Sustained Knockdown of CD95L Induces Cell Death.
  • Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V3, Kolesza P, Richards J, Chandel N, Djaballah H, Peter ME

  • Cell Rep. 2014 Apr 10;7(1):208-22.

2014-07-29

Fig 2. Averaged cumulative DVHs over the rectum (left) and the rectal wall (right) for the BCCA cohort (upper two figures) and AUH cohort (bottom two figures). The DVHs from the originally acquired slice thicknesses in 5 and 3 mm, respectively, are shown in black.

Fig 2. Averaged cumulative DVHs over the rectum (left) and the rectal wall (right) for the BCCA cohort (upper two figures) and AUH cohort (bottom two figures). The DVHs from the originally acquired slice thicknesses in 5 and 3 mm, respectively, are shown in black.
  • Olsson C, Thor M, Liu M, Moissenko V, Petersen SE, Høyer M, Apte A, Deasy JO

  • Phys Med Biol. 2014 Jul 21;59(14):3749-59.

2014-07-30

Fig 1. NIH Expenditures vs. GDP 1984–2013.

Fig 1. NIH Expenditures vs. GDP 1984–2013.
  • Kelly T, Marians K

  • Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2632-3

2014-07-31

Model Illustrating the Mechanism by which CRL4DCAF1 Promotes Oncogenesis

Model Illustrating the Mechanism by which CRL4DCAF1 Promotes Oncogenesis
  • Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO, Zhou P, Karajannis MA, Giancotti FG

  • Cancer Cell. 2014 Jul 14;26(1):48-60.

2014-08-01

Structural basis for multivalent readout of histone marks from a single histone tail.

Structural basis for multivalent readout of histone marks from a single histone tail.
  • Du J, Patel DJ

  • Biochim Biophys Acta. 2014 Aug;1839(8):719-727.

2014-08-04

GLV-1h68 infection of parental hepatocellular carcinoma (HCC) and sorafenib-resistant HCC cell lines shows similar time- and concentration-dependent infection in vitro.

GLV-1h68 infection of parental hepatocellular carcinoma (HCC) and sorafenib-resistant HCC cell lines shows similar time- and concentration-dependent infection in vitro.
  • Ady JW1, Heffner J1, Mojica K1, Johnsen C1, Belin LJ1, Love D1, Chen CT1, Pugalenthi A1, Klein E1, Chen NG2, Yu YA2, Szalay AA3, Fong Y4

  • Surgery. 2014 Aug;156(2):263-9.

2014-08-05

Flow diagram of patients with testicular sex-cord stromal tumors treated at MSKCC.

Flow diagram of patients with testicular sex-cord stromal tumors treated at MSKCC.
  • Silberstein JL, Bazzi WM, Vertosick E, Carver BS, Bosl GJ, Feldman DR, Bajorin DF, Motzer RJ, Al-Ahmadie H, Reuter VE, Sheinfeld J.

  • J Urol. 2014 Aug;192(2):415-9.

2014-08-06

Fig 1. Proposed Model for Notch-Mediated Contributions to Myeloid Disease Pathogenesis

Fig 1. Proposed Model for Notch-Mediated Contributions to Myeloid Disease Pathogenesis
  • Khalaj M, Park CY

  • Cell Stem Cell. 2014 Jul 3;15(1):1-2.

2014-08-07

Left ventricular ejection fraction (LVEF) over time in individual patients after symptomatic decrease in LVEF on sunitinib

Left ventricular ejection fraction (LVEF) over time in individual patients after symptomatic decrease in LVEF on sunitinib
  • Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ

  • Eur J Cancer. 2014 Aug;50(12):2162-70.

2014-08-08

Model Summarizing Key Aspects of the Regulation and Function of RAB7 Described in This Study

Model Summarizing Key Aspects of the Regulation and Function of RAB7 Described in This Study
  • Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E, Cifdaloz M, Karras P, Osterloh L, Megías D, Cañón E, Calvo TG, Olmeda D, Gómez-López G, Graña O, Sánchez-Arévalo Lobo VJ, Pisano DG, Wang HW, Ortiz-Romero P, Tormo D, Hoek K, Rodríguez-Peralto JL, Joyce JA, Soengas MS

  • Cancer Cell. 2014 Jul 14;26(1):61-76.

2014-08-11

Lancet. 2014 Jul 12;384(9938):164-72.

Lancet. 2014 Jul 12;384(9938):164-72.
  • Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J1, Perou C1, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G

  • Lancet. 2014 Jul 12;384(9938):164-72.

2014-08-12

Knockdown of Mutant p53 in Pancreatic Cancer Cells Alters a Myriad of Genes and Pathways.

Knockdown of Mutant p53 in Pancreatic Cancer Cells Alters a Myriad of Genes and Pathways.
  • Weissmueller S, Manchado E, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, Prives C, Biankin AV, Lowe SW

  • Cell. 2014 Apr 10;157(2):382-94.

2014-08-13

Fig 1. Serum BKV IgG titers and BK viruria. X-axis: pretransplantation serum BKV IgG titers. Y-axis: percentage of patients.

Fig 1. Serum BKV IgG titers and BK viruria. X-axis: pretransplantation serum BKV IgG titers. Y-axis: percentage of patients.
  • Lee YJ, Zheng J, Kolitsopoulos Y, Chung D, Amigues I, Son T, Choo K, Hester J, Giralt SA, Glezerman IG, Jakubowski AA, Papanicolaou GA

  • Biol Blood Marrow Transplant. 2014 Aug;20(8):1204-10

2014-08-14

Fig 1. PFS by GEP70 risk in TT6 for previously treated, but nontransplanted, patients.

Fig 1. PFS by GEP70 risk in TT6 for previously treated, but nontransplanted, patients.
  • van Rhee F, Giralt S, Barlogie B

  • Blood. 2014 Jul 17;124(3):328-333.

2014-08-15

Fig 1. TAMs induce resistance to gemcitabine in human PDAC.

Fig 1. TAMs induce resistance to gemcitabine in human PDAC.
  • Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, Gil Z

  • Oncogene. 2014 Jul 17;33(29):3812-9.

2014-08-19

Fig 1. Translational medicine as a means to rapid drug discovery. Triggers prompt transition of drugs from the scientist’s bench to the patient’s bedside. Illustration is courtesy of Wenjing Wu, from Medical Graphics at MSKCC.

Fig 1. Translational medicine as a means to rapid drug discovery. Triggers prompt transition of drugs from the scientist’s bench to the patient’s bedside. Illustration is courtesy of Wenjing Wu, from Medical Graphics at MSKCC.
  • Bhinder B, Djaballah H

  • ACS Chem Biol. 2014 Jul 18;9(7):1394-7.

2014-08-20

Fig 1. An X chromosome region characterized by high sequence divergence, coupled with low Tajima’s D values, as well as high TE differentiation.

Fig 1. An X chromosome region characterized by high sequence divergence, coupled with low Tajima’s D values, as well as high TE differentiation.
  • Kim YB, Oh JH, McIver LJ, Rashkovetsky E, Michalak K, Garner HR, Kang L, Nevo E, Korol AB, Michalak P

  • Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10630-5.

2014-08-21

Fig 6. CD44 may be a response biomarker in patients with advanced gastric and gastroesophageal cancer treated with chemotherapy with or without vismodegib. C, Kaplan–Meier overall survival curves for patients receiving chemotherapy alone and patients receiving chemotherapy plus vismodegib stratified by low and high CD44 score.

Fig 6. CD44 may be a response biomarker in patients with advanced gastric and gastroesophageal cancer treated with chemotherapy with or without vismodegib. C, Kaplan–Meier overall survival curves for patients receiving chemotherapy alone and patients receiving chemotherapy plus vismodegib stratified by low and high CD44 score.
  • Yoon C, Park do J, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS

  • Clin Cancer Res. 2014 Aug 1;20(15):3974-88.

2014-08-22

Fig 1. Distribution of pHLIPs in small 4T1 mammary tumors, muscle, kidney, and liver.

Fig 1. Distribution of pHLIPs in small 4T1 mammary tumors, muscle, kidney, and liver.
  • Adochite RC1, Moshnikova A, Carlin SD, Guerrieri RA, Andreev OA, Lewis JS, Reshetnyak YK

  • Mol Pharm. 2014 Aug 4;11(8):2896-905.

2014-08-25

Fig 2. Illustration of intervention materials used in the DAMES (Daughters and MothErS Against Breast Cancer) trial is shown.

Fig 2. Illustration of intervention materials used in the DAMES (Daughters and MothErS Against Breast Cancer) trial is shown.
  • Demark-Wahnefried W, Jones LW, Snyder DC, Sloane RJ, Kimmick GG, Hughes DC, Badr HJ, Miller PE, Burke LE, Lipkus IM

  • Cancer. 2014 Aug 15;120(16):2522-34

2014-08-26

Fig 1. 1298case –FISH + for ALK variant (green probe missing).

Fig 1. 1298case –FISH + for ALK variant (green probe missing).
  • Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE

  • PLoS One. 2014 Aug 1;9(8):e103325
Open Access button

2014-08-27

Graphical Abstract

Graphical Abstract
  • Du J, Johnson LM, Groth M, Feng S, Hale CJ, Li S, Vashisht AA, Gallego-Bartolome J, Wohlschlegel JA, Patel DJ, Jacobsen SE

  • Mol Cell. 2014 Aug 7;55(3):495-504.

2014-08-28

Fig 1. ESKM is more efficacious and potent in ADCC assays with human PBMC effectors at the indicated mAb concentrations and effector/target (E:T) ratios. Cytotoxicity was measured by 4-hour 51Cr release assay

Fig 1. ESKM is more efficacious and potent in ADCC assays with human PBMC effectors at the indicated mAb concentrations and effector/target (E:T) ratios. Cytotoxicity was measured by 4-hour 51Cr release assay
  • Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA

  • Clin Cancer Res. 2014 Aug 1;20(15):4036-46

2014-08-29

Fig 6a. E−KTS induces partial neural reprogramming. A, E−KTS and E+KTS MEFs cultured with or without 1 μmol/L 4-HT were cultured for 10 days in N2-containing media. Cells were immunostained with Tuj1 antibody and DAPI; scale bar, 20 μm.

Fig 6a. E−KTS induces partial neural reprogramming. A, E−KTS and E+KTS MEFs cultured with or without 1 μmol/L 4-HT were cultured for 10 days in N2-containing media. Cells were immunostained with Tuj1 antibody and DAPI; scale bar, 20 μm.
  • Kang HJ, Park JH, Chen W, Kang SI, Moroz K, Ladanyi M, Lee SB

  • Cancer Res. 2014 Aug 15;74(16):4526-35.
Open Access button

2014-09-02

Fig 7b. CDK9 is required for initiation and maintenance of MYC-overexpressing liver tumors. Representative bright-field and fluorescent images of the livers in A. Tumors are positive for GFP.

Fig 7b. CDK9 is required for initiation and maintenance of MYC-overexpressing liver tumors. Representative bright-field and fluorescent images of the livers in A. Tumors are positive for GFP.
  • Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW

  • Genes Dev. 2014 Aug 15;28(16):1800-14.

2014-09-03

Fig 1. Cumulative incidence of infectious complications.

Fig 1. Cumulative incidence of infectious complications.
  • Perkins JL, Chen Y, Harris A, Diller L, Stovall M, Armstrong GT, Yasui Y, Robison LL, Sklar CA; Childhood Cancer Survivor Study

  • Cancer. 2014 Aug 15;120(16):2514-21.

2014-09-04

Fig 1. Progression-free survival (PFS) and overall survival (OS) of 79 stage 4 patients treated with 3F8 + scGM-CSF for primary refractory neuroblastoma.

Fig 1. Progression-free survival (PFS) and overall survival (OS) of 79 stage 4 patients treated with 3F8 + scGM-CSF for primary refractory neuroblastoma.
  • Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH

  • Int J Cancer. 2014 Nov 1;135(9):2199-205.

2014-09-05

Fig 1. Methylation profiles of primary tumors are maintained in regional metastasis but display molecular subtype-specific differences. A. Dendogram shows unsupervised hierarchical clustering of methylation data from 44 matched primary breast carcinomas and regional metastases.

Fig 1. Methylation profiles of primary tumors are maintained in regional metastasis but display molecular subtype-specific differences. A. Dendogram shows unsupervised hierarchical clustering of methylation data from 44 matched primary breast carcinomas and regional metastases.
  • Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA

  • PLoS One. 2014 Aug 1;9(8):e103896.
Open Access button

2014-09-08

Fig 1. Probability of event free survival.

Fig 1. Probability of event free survival.
  • Soni S, Boulad F, Cowan MJ, Scaradavou A, Dahake J, Edwards S, Walters MC

  • Pediatr Blood Cancer. 2014 Sep;61(9):1690-4.

2014-09-09

Fig 1. EGFR, HER2 and HER3 protein expression in ESCC and EAC tissue specimens.

Fig 1. EGFR, HER2 and HER3 protein expression in ESCC and EAC tissue specimens.
  • Fichter CD, Timme S, Braun JA, Gudernatsch V, Schöpflin A, Bogatyreva L, Geddert H, Faller G, Klimstra D, Tang L, Hauschke D, Werner M, Lassmann S

  • Int J Cancer. 2014 Oct 1;135(7):1517-30.

2014-09-10

Fig 1. Mitral apparatus perfusion categories.

Fig 1. Mitral apparatus perfusion categories.
  • Volo SC, Kim J, Gurevich S, Petashnick M, Kampaktsis P, Feher A, Szulc M, Wong FJ, Devereux RB, Okin PM, Girardi LN, Min JK, Levine RA, Weinsaft JW

  • Am J Cardiol. 2014 Aug 1;114(3):355-61.

2014-09-11

Fig 3B. 
Combined first-line and second-line (A) progression-free survival (PFS; Kaplan-Meier [K-M]) and (B) overall survival (OS; K-M). EVE, everolimus; SUN, sunitinib.

Fig 3B. Combined first-line and second-line (A) progression-free survival (PFS; Kaplan-Meier [K-M]) and (B) overall survival (OS; K-M). EVE, everolimus; SUN, sunitinib.
  • Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ

  • J Clin Oncol. 2014 Sep 1;32(25):2765-72.

2014-09-12

Fig 1. Kaplan-Meier curve for overall survival for the 12 patients treated with pralatrexate.

Fig 1. Kaplan-Meier curve for overall survival for the 12 patients treated with pralatrexate.
  • Ho AL, Lipson BL, Sherman EJ, Xiao H, Fury MG, Apollo A, Seetharamu N, Sima CS, Haque S, Lyo JK, Sales R, Cox L, Pfister DG

  • Invest New Drugs. 2014 Jun;32(3):549-54.

2014-09-15

Fig 2. The best individual changes in total lesion size from baseline are illustrated for all sarcoma types. WHO indicates World Health Organization classification; PR, partial response; SD, stable disease; PD, progressive disease.

Fig 2. The best individual changes in total lesion size from baseline are illustrated for all sarcoma types. WHO indicates World Health Organization classification; PR, partial response; SD, stable disease; PD, progressive disease.
  • Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, Chawla SP, Maki RG, Araujo DM, Geoerger B, Ganjoo K, Marina N, Blay JY, Schuetze SM, Chow WA, Helman LJ

  • Cancer. 2014 Aug 15;120(16):2448-56.

2014-09-16

Fig 1h. FISH analysis of the 19q13.42 locus (b, e, h), LIN28A immunohistochemistry.

Fig 1h. FISH analysis of the 19q13.42 locus (b, e, h), LIN28A immunohistochemistry.
  • Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones DT, Remke M, Northcott P, Perry A, Picard D, Rosenblum M, Antonelli M, Aronica E, Schüller U, Hasselblatt M, Woehrer A, Zheludkova O, Kumirova E, Puget S, Taylor MD, Giangaspero F, Peter Collins V, von Deimling A, Lichter P, Huang A, Pietsch T, Pfister SM, Kool M

  • Acta Neuropathol. 2014 Aug;128(2):279-89.
Open Access button

2014-09-17

Fig 1. Illustration of the difference between survivor fraction (solid curve) and TCP (dashed curve) for a hypothetical treatment.

Fig 1. Illustration of the difference between survivor fraction (solid curve) and TCP (dashed curve) for a hypothetical treatment.
  • Hanin L, Zaider M.

  • Phys Med Biol. 2014 Jul 21;59(14):3829-42.

2014-09-18

FIGURE 1. A, Most of the carcinomas were composed of basaloid nests and lobules with intervening desmoplastic stroma (case 3). B, All tumors exhibited complete loss of SMARCB1 immunostaining, with stromal and inflammatory cells serving as an internal positive control (case 3).

FIGURE 1. A, Most of the carcinomas were composed of basaloid nests and lobules with intervening desmoplastic stroma (case 3). B, All tumors exhibited complete loss of SMARCB1 immunostaining, with stromal and inflammatory cells serving as an internal positive control (case 3).
  • Bishop JA, Antonescu CR, Westra WH

  • Am J Surg Pathol. 2014 Sep;38(9):1282-9.

2014-09-19

Figure 1A.Magnetic field exposure systems. Photos of 125 kHz (a) and 13.56 MHz.

Figure 1A.Magnetic field exposure systems. Photos of 125 kHz (a) and 13.56 MHz.
  • Seidman SJ1, Bekdash O, Guag J, Mehryar M, Booth P, Frisch P

  • Biomed Eng Online. 2014 Aug 3;13:110.
Open Access button

2014-09-22

Figure 1. Receiver operating characteristic (ROC) curves for risk prediction involving later non-elective operative delivery.

Figure 1. Receiver operating characteristic (ROC) curves for risk prediction involving later non-elective operative delivery.
  • Baker SG, Schuit E, Steyerberg EW, Pencina MJ, Vickers A, Moons KG, Mol BW, Lindeman KS

  • Stat Med. 2014 Sep 28;33(22):3946-59
Open Access button

2014-09-23

Fig 2.(A) Iso-fludelone chromatograms of control plasma (bottom line) and an LLQ plasma sample (upper line, 100 counts off-set). (B) Internal standard chromatograms of control plasma (bottom line) and an LLQ plasma sample (upper line, 500 counts off-set).

Fig 2.(A) Iso-fludelone chromatograms of control plasma (bottom line) and an LLQ plasma sample (upper line, 100 counts off-set). (B) Internal standard chromatograms of control plasma (bottom line) and an LLQ plasma sample (upper line, 500 counts off-set).
  • Christner SM, Parise RA, Levine ED, Rizvi NA, Gounder MM, Beumer JH

  • J Pharm Biomed Anal. 2014 Aug 12;100C:199-204.

2014-09-24

Fig 1. dAd5GNE generated anticocaine antibody specificity for cocaine compared with cocaine metabolites.

Fig 1. dAd5GNE generated anticocaine antibody specificity for cocaine compared with cocaine metabolites.
  • Hicks MJ, Kaminsky SM, De BP, Rosenberg JB, Evans SM, Foltin RW, Andrenyak DM, Moody DE, Koob GF, Janda KD, Ricart Arbona RJ, Lepherd ML, Crystal RG

  • Hum Gene Ther Clin Dev. 2014 Mar;25(1):40-9.

2014-09-25

Fig B. Essential role for PD-L1 blockade in viral control after T reg cell depletion. Foxp3DTR knock-in mice chronically infected with LCMV received DT for 10 d (as in Fig. 2) in combination with PD-L1 blocking antibody. PD-L1 antibody was administered on days 1, 4, and 7 of DT treatment. Fold reduction in serum viral titer after treatment.

Fig B. Essential role for PD-L1 blockade in viral control after T reg cell depletion. Foxp3DTR knock-in mice chronically infected with LCMV received DT for 10 d (as in Fig. 2) in combination with PD-L1 blocking antibody. PD-L1 antibody was administered on days 1, 4, and 7 of DT treatment. Fold reduction in serum viral titer after treatment.
  • Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, O'Mara L, Yang S, Konieczny BT, Sharpe AH, Freeman GJ, Rudensky AY, Ahmed R

  • J Exp Med. 2014 Aug 25;211(9):1905-18.

2014-09-26

Fig 1B. Asymptomatic 69-year-old woman with incidental esophageal gastrointestinal stromal tumor on imaging studies. Left posterior oblique spot image from double-contrast barium esophagogram shows 4-cm smooth submucosal mass (arrow) compressing lumen of distal right esophagus by more than 75%, without obstruction.

Fig 1B. Asymptomatic 69-year-old woman with incidental esophageal gastrointestinal stromal tumor on imaging studies. Left posterior oblique spot image from double-contrast barium esophagogram shows 4-cm smooth submucosal mass (arrow) compressing lumen of distal right esophagus by more than 75%, without obstruction.
  • Winant AJ, Gollub MJ, Shia J, Antonescu C, Bains MS, Levine MS

  • AJR Am J Roentgenol. 2014 Aug;203(2):306-14

2014-09-29

Fig 1. Flow diagram representing the guidelines followed in the selection of the patients suitable for the present study.

Fig 1. Flow diagram representing the guidelines followed in the selection of the patients suitable for the present study.
  • Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G

  • BMC Cancer. 2014 Jul 21;14(1):529.
Open Access button

2014-09-30

Fig 6. Distribution of long-term survivors from 3 datasets among the The Cancer Genome Atlas transcriptional subtypes.

Fig 6. Distribution of long-term survivors from 3 datasets among the The Cancer Genome Atlas transcriptional subtypes.
  • Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA

  • Neuro Oncol. 2014 Sep;16(9):1186-95.

2014-10-01

Fig 3. Kaplan-Meier 10-year breast cancer-specific survival analyses in the molecular taxonomy of breast cancer international consortium dataset (all patients). B) Based on intrinsic subtype and cHER2 status.

Fig 3. Kaplan-Meier 10-year breast cancer-specific survival analyses in the molecular taxonomy of breast cancer international consortium dataset (all patients). B) Based on intrinsic subtype and cHER2 status.
  • Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J

  • J Natl Cancer Inst. 2014 Aug 19;106(8). pii: dju152.